Semaglutide was originally created to treat patients with diabetes, however, a secondary application was later found as a medicine used for weight loss, to lower blood sugar levels, and to reduce the risk of major cardiovascular events such as heart attack or stroke in type two diabetes patients
John SK, Rangan Y, Block CA, Koff MD
Additionally, GLP-1 shots should be part of a comprehensive treatment plan that includes lifestyle modifications such as diet and exercise
Current practice converges around three tiers: The split-dose protocol (250 mcg morning, 250 mcg 3+ hours post-meal in the evening) creates two daily windows of lipolytic stimulation
Focus on next-generation products Novo is investing in next-generation GLP-1 therapies, including oral semaglutide formulations and combination drugs like CagriSema, which may offer enhanced efficacy compared to current products